Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29360593 | 0.92 | TSHR (0.46) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL8623356 | 0.91 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Fluoride Ion SCHEMBL17601912 | 0.90 | TSHR (0.45) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL2507036 | 0.89 | TSHR (0.42) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL29354050 | 0.89 | TSHR (0.42) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL30943478 | 0.88 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL27808614 | 0.88 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| Phosphine SCHEMBL28247442 | 0.88 | TSHR (0.41) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL853363 | 0.87 | TSHR (0.39) | TSHRNPSR1RXFP1KMT2AMAPK1 | |
| SCHEMBL4956436 | 0.87 | KMT2A (0.44) | TSHRNPSR1RXFP1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2792677-B1 | Novel compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2017-04-26 | — | — | EP | disclosed |
| EP-2702059-B1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2015-08-19 | — | — | EP | disclosed |
| EP-2792677-A1 | Novel compound useful for the treatment of degenerative and inflammatory diseases | Galapagos N.V. (BE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2445912-B1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| CN-101801938-A | Non-basic melanin concentrating hormone receptor body-1 antagonist and method | BRISTOL MYERS SQUIBB CO | 2010-08-11 | — | — | CN | disclosed |
| EP-2173725-A2 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | Bristol-Myers Squibb Company (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009071707-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009009501-A2 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090011994-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090011994-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MCHR2, MC1R | TSHR 28/4885NPSR1 21/4885RXFP1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.